Drug-induced movement disorders and tardive dyskinesia

01OverviewDefinition, clinical context and the essential points that orientate the chapter.

The same dopamine-blocking exposure can produce several movement syndromes at different times. Acute dystonia is patterned and sustained, often involving the neck, jaw, eyes or tongue. Akathisia is subjective as well as visible; ask whether movement relieves an unbearable inner restlessness. Parkinsonism reduces movement and facial expression and may be confused with negative symptoms or depression. Tardive dyskinesia is delayed and often hyperkinetic, with chewing, tongue protrusion, grimacing and limb or trunk movements. Tardive dystonia and akathisia also occur.

Risk relates to potency, dose, duration, age, underlying neurological disease, diabetes and cumulative exposure, but no antipsychotic is risk free. Acute dystonia is more common in younger people and after rapid dose increase. Drug-induced parkinsonism is common in older adults and can unmask preclinical Parkinson disease; persistence after withdrawal may justify dopaminergic imaging or specialist reassessment. Tardive movements can be masked temporarily by increasing the blocker, a misleading improvement that increases long-term exposure.

Care must balance neurological harm and psychiatric relapse. The prescriber, patient and mental-health team should review whether the medicine remains needed, whether dose reduction is safe, and whether a lower-risk agent such as clozapine is appropriate. Off-label VMAT2 treatment and antipsychotic changes require specialist authorisation under local psychiatry, pharmacy, toxicology and movement-disorder protocols.

Key points

Acute dystonia usually appears within hours to several days of a dopamine-blocking medicine or dose increase and causes painful sustained neck, jaw, eye, tongue or trunk postures.
Akathisia is a distressing inner inability to keep still with pacing, rocking or repeated leg movement; it is commonly mistaken for agitation or worsening psychosis.
Drug-induced parkinsonism develops over days to months with bradykinesia, rigidity and often bilateral symptoms, although asymmetry does not completely exclude a medication contribution.
Tardive dyskinesia follows cumulative dopamine-receptor-blocking exposure and commonly produces repetitive oro-bucco-lingual, chewing, choreiform or athetoid movements that can persist after the drug stops.
Antipsychotics are major causes, but metoclopramide and prochlorperazine are important non-psychiatric exposures; reconcile antiemetics, depot injections and remote courses.
Neuroleptic malignant syndrome combines dopamine-blocker exposure or dopaminergic withdrawal with rigidity, hyperthermia, altered mental state, autonomic instability and often raised creatine kinase.
Document a baseline and serial movement examination during antipsychotic treatment because patients may not notice early tongue or finger movements.
Management starts by identifying the syndrome, reviewing dose and indication, and reducing, stopping or switching collaboratively; abrupt antipsychotic withdrawal can destabilise serious mental illness.
Anticholinergics treat acute dystonia and sometimes short-term parkinsonism but can worsen tardive dyskinesia and cause cognitive, urinary, ocular and gastrointestinal harm.
Persistent tardive syndromes require specialist psychiatry and movement-disorder input for lowest-risk antipsychotic strategy and possible VMAT2-directed treatment.

02AetiologyUnderlying causes, associations and risk factors, with why each one matters.

Dopamine-receptor blockade

Antipsychotics and dopamine-blocking antiemetics can cause acute dystonia, akathisia and parkinsonism, particularly after initiation, dose increase or parenteral exposure.

Cumulative tardive exposure

Longer dopamine-blocker exposure increases risk of persistent oro-bucco-lingual, choreiform or dystonic movements, although tardive syndromes can appear after shorter courses.

Dopaminergic withdrawal and other medicines

Abrupt withdrawal of Parkinson treatment can cause severe rigidity, while lithium, valproate, stimulants and serotonergic medicines produce tremor, myoclonus or other movement phenotypes.

03PathophysiologyThe causal sequence from the underlying abnormality to symptoms and harm.

1
Acute pathway imbalance
Dopamine blockade disrupts basal-ganglia balance, causing excessive cholinergic influence and patterned dystonia or reduced movement with rigidity.
2
Subjective motor drive
Altered striatal signalling can generate an uncomfortable internal need to move, expressed as pacing, rocking and inability to remain still in akathisia.
3
Receptor and circuit adaptation
Chronic blockade promotes receptor supersensitivity and maladaptive plasticity, allowing repetitive involuntary tardive movements that may persist after the medicine stops.

04Clinical features and red flagsSymptoms, examination findings, patterns of presentation and time-critical warnings.

Acute dystoniaRed flag

Torticollis, jaw spasm, tongue protrusion, opisthotonus or sustained upward eye deviation soon after dopamine blockade is a painful acute dystonic reaction until an alternative is shown.

AkathisiaRed flag

Subjective inner torment with pacing, shifting weight and inability to sit after antipsychotic initiation or increase should be named and assessed for self-harm rather than dismissed as non-compliance.

Drug-induced parkinsonism

Bradykinesia, reduced expression, rigidity, shuffling and tremor emerging during dopamine-receptor blockade suggests medication effect, particularly when bilateral and temporally linked.

Tardive dyskinesia

Persistent lip smacking, chewing, tongue, facial, distal limb or trunk movements after months or years of exposure support a tardive syndrome and require structured severity recording.

Neuroleptic malignant syndromeRed flag

Fever, generalised rigidity, confusion, tachycardia, labile blood pressure and raised creatine kinase after dopamine blockade is a life-threatening systemic syndrome.

05InvestigationsWhat to request, why it matters and how to interpret it.

Investigation order

Read from the initial assessment onwards. Tests may run in parallel in urgent care; first-line, preferred, confirmatory, definitive and gold-standard labels appear only when the chapter explicitly states them.

01
Complete exposure timelineFirst step
Why
Link syndrome onset to antipsychotic, antiemetic, antidepressant, dopaminergic and withdrawal events.
Interpretation and limitations
Include depot dates, as-required administration, emergency antiemetics and medicines recently stopped. A delayed tardive syndrome may become more visible after dose reduction.
02
Structured movement examination
Why
Separate dystonia, akathisia, parkinsonism and dyskinesia and create a reproducible baseline.
Interpretation and limitations
Observe face, mouth, tongue, hands, trunk, gait and seated rest; pair an objective scale with the patient’s subjective distress and functional impact.
03
Acute physiological and laboratory assessment
Why
Identify neuroleptic malignant syndrome, serotonin toxicity and complications of severe movement.
Interpretation and limitations
Check temperature, consciousness, autonomic observations, hydration, renal function, electrolytes, CK, blood count and liver tests as indicated; severe syndromes remain clinical diagnoses requiring immediate treatment.
04
Neurological reassessment after medicine change
Why
Determine whether persistent parkinsonism reflects unmasked degenerative disease or tardive movement remains despite withdrawal.
Interpretation and limitations
Recovery may take weeks or months. Persistent asymmetric bradykinesia, non-motor Parkinson features or progression merits movement-disorder review and selected dopaminergic imaging.
05
ECG and physical-health monitoring
Why
Support safe antipsychotic or beta-blocker adjustment and quantify wider treatment burden.
Interpretation and limitations
QT, pulse, blood pressure, weight, glycaemia and lipids influence selection but do not replace movement surveillance. Use the current psychiatric protocol and medicine-specific risks.

06Differential diagnosisRealistic alternatives and the features that help distinguish them.

Idiopathic Parkinson disease

Asymmetric rest tremor, non-motor prodrome and sustained levodopa response favour degenerative disease, although dopamine blockers can unmask previously subclinical parkinsonism.

Psychiatric agitation

Goal-directed restless behaviour linked to thought or emotion differs from the distressing inner motor urge of akathisia; careful subjective history prevents dose escalation.

Neuroleptic malignant syndrome

Fever, altered mental state, generalised rigidity and autonomic instability indicate a life-threatening systemic syndrome rather than uncomplicated drug-induced parkinsonism.

Primary chorea, dystonia or tics

Family history, childhood onset, stereotyped urge or movement preceding drug exposure supports an independent movement disorder, while chronology remains central.

07ManagementImmediate care, first-line treatment, alternatives and escalation.

01Acute reactionRelieve dystonia and protect airwayFirst stepA painful patterned posture or oculogyric crisis begins soon after a dopamine blocker.

11. Assess airway, breathing, swallowing and laryngeal involvement, stop further culprit doses and call emergency support when speech, stridor or ventilation is affected.
22. Give protocol-dose parenteral procyclidine or the locally recommended anticholinergic and observe for response and recurrence.
33. Document the drug and reaction prominently, review continuing oral cover where indicated and notify the prescribing team before any rechallenge.
44. Reconsider seizure, tetany, strychnine toxicity and structural disease if the response or phenomenology is atypical.

02New restlessness or slownessSeparate adverse effect from illnessPacing, agitation, bradykinesia or rigidity emerges during psychiatric or antiemetic treatment.

11. Ask explicitly about inner restlessness and relief with movement, then examine bradykinesia, rigidity, tremor, affect and cognition.
22. Map onset to dose, depot and interacting medicines and assess suicidality, falls, swallowing and ability to engage with care.
33. Agree dose reduction, switch or cautious symptomatic treatment with the mental-health prescriber, avoiding abrupt destabilising cessation when no emergency exists.
44. Review after an adequate washout trajectory and refer persistent, progressive or asymmetric signs for neurological assessment.

03TardiveReduce cumulative harmDelayed repetitive dyskinetic or dystonic movements persist during or after dopamine blockade.

11. Confirm the phenomenology and quantify functional impact with baseline video or a structured scale, checking dentures and other mimics.
22. Review every dopamine blocker and anticholinergic, the ongoing psychiatric indication and previous relapse history in a shared multidisciplinary meeting.
33. Use the minimum effective exposure, consider a lower-risk antipsychotic and seek movement-disorder advice for disabling persistent symptoms or VMAT2 treatment.
44. Monitor both movement and mental state through any gradual change, explaining that symptoms may persist or transiently unmask after reduction.

Key medicines and prescribing safety3 treatments · regimens, roles and cautions

Rapidly reverses acute dopamine-blocker-related dystonic spasm and can be life-saving when laryngeal muscles are involved.

Parenteral procyclidine for acute dystonia

A common adult emergency regimen is 5–10 mg intramuscularly or intravenously, with one repeat after about 20 minutes if needed within the current local maximum and observation protocol.

Continue airway assessment and do not assume response proves the cause. Watch confusion, tachycardia, urinary retention, glaucoma and anticholinergic toxicity; short oral cover may be prescribed to prevent recurrence.

Can reduce antipsychotic-induced akathisia when dose reduction or switching is insufficient or cannot occur immediately.

Propranolol for selected akathisia

After cardiovascular assessment, a specialist may start 10 mg two or three times daily and titrate cautiously to subjective and objective response under local guidance.

Avoid in asthma, bradycardia, hypotension or significant conduction disease and consider masking of hypoglycaemia. It does not replace urgent assessment of suicidal distress.

Reduces presynaptic monoamine packaging and may suppress functionally disabling persistent tardive movements when exposure optimisation is insufficient.

VMAT2-directed treatment for tardive dyskinesia

Choice, starting dose and titration depend on the commissioned specialist medicine and current formulary; treatment should occur through movement-disorder and psychiatry services with a documented baseline scale.

Availability and licensing differ between agents. Monitor depression, suicidality, sedation, parkinsonism, akathisia, QT risk and interactions, and preserve necessary psychiatric treatment.

08ComplicationsImportant consequences, why they occur and why they matter clinically.

Airway compromise

Acute laryngeal, pharyngeal or jaw dystonia can obstruct breathing or swallowing and requires emergency recognition and treatment.

Persistent tardive disability

Tardive dyskinesia may remain after withdrawal, affecting speech, eating, walking, appearance and social participation over time.

Falls, aspiration and pain

Rigidity, sedation, dysphagia and abnormal postures increase falls, aspiration, musculoskeletal pain, loss of mobility and functional dependence.

Psychiatric destabilisation

Abruptly stopping essential antipsychotic treatment can precipitate relapse, self-harm or admission, so movement and mental-health risks require coordinated decisions.

09Monitoring and follow-upTreatment response, safety checks and longer-term review.

Record a movement baseline before and during antipsychotic therapy, inspecting mouth, tongue, face, fingers, trunk and gait rather than relying on spontaneous complaint.
During titration ask separately about inner restlessness, because akathisia can be intensely distressing despite modest visible movement.
Monitor temperature, autonomic state, hydration, CK and renal function urgently when rigidity or systemic illness suggests neuroleptic malignant syndrome.
Follow mental state, sleep, adherence and relapse warning signs alongside neurological change during any antipsychotic reduction or switch.
Measure tardive treatment against speech, eating, walking, pain and social participation, while tracking depression, parkinsonism and cardiac adverse effects.

10Special situationsVariants, exceptions and circumstances that change the usual approach.

Akathisia feels worse

The subjective drive to move may be more distressing than pacing looks and has important links to treatment refusal, aggression and suicidal thinking.

Dose increase can mask tardive movement

More dopamine blockade may temporarily suppress dyskinesia, creating false improvement while increasing cumulative exposure and future persistence.

Antiemetics count

Metoclopramide and prochlorperazine are dopamine blockers, so an acute neck spasm or delayed oral movement may originate outside psychiatric prescribing.

Parkinsonism can unmask disease

A medicine may reveal latent Parkinson disease rather than being the sole cause, particularly when asymmetry and progression continue after withdrawal.

Anticholinergics are syndrome-specific

They rapidly treat acute dystonia but can worsen cognition, constipation, urinary retention and tardive dyskinesia when continued without a clear indication.

11Common pitfallsFrequent interpretation and management errors.

01
Labelling akathisia agitation may prompt a higher antipsychotic dose, intensifying restlessness and suicide risk.
02
Missing a dopamine-blocking antiemetic in medication reconciliation can lead to unnecessary neurological investigation and repeat exposure.
03
Continuing procyclidine indefinitely for tardive dyskinesia can worsen the movement and add a major anticholinergic burden.
04
Stopping an essential antipsychotic abruptly outside an emergency can precipitate relapse and destroy trust in management of the adverse effect.
05
Using creatine kinase as the sole test for neuroleptic malignant syndrome delays treatment of a clinical emergency when the result is initially modest.